NCT04781933 (ICAN) is a NA clinical trial of Treatment with Combo in NASH - Nonalcoholic Steatohepatitis, sponsored by Mativa-Tech SA.

Who is sponsoring NCT04781933?

NCT04781933 is sponsored by Mativa-Tech SA.

What drugs are being tested in NCT04781933?

Interventions in NCT04781933: Treatment with Combo, Treatment with placebo.

What condition does NCT04781933 study?

NCT04781933 studies NASH - Nonalcoholic Steatohepatitis.

Is NCT04781933 still recruiting?

NCT04781933 is currently status unknown. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT04781933: ICAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement

Status unknown NA Last updated 7 November 2023

What this trial tests

NA trial testing Treatment with Combo in NASH - Nonalcoholic Steatohepatitis in 60 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2024

1 January 2025

Quick facts

Lead sponsor	Mativa-Tech SA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 January 2023
Primary completion	1 January 2024
Estimated completion	1 January 2025
Sites	2 locations across France

Drugs / interventions tested

Treatment with Combo
Treatment with placebo — full drug profile →

Conditions studied

NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →

Sponsor

Mativa-Tech SA

Who can join

Adults 18 to 75, any sex, with NASH - Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this bicentre, prospective, placebo-controlled, double-blind, randomized, interventional study is to assess for the first time the effects of a Combo with probiotics and dietary supplements compared to placebo for non-alcoholic steatohepatitis (NASH) patients with mild or severe fibrosis.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Gut liver brain axis in diseases: the implications for therapeutic interventions.
Yan M, Man S, Sun B, Ma L, et al · · 2023 · cited 165× · PMID 38057297 · DOI 10.1038/s41392-023-01673-4
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
Yang YY, Xie L, Zhang NP, Zhou D, et al · · 2022 · cited 42× · PMID 35190696 · DOI 10.1038/s41401-022-00860-3
Vitamin E for people with non-alcoholic fatty liver disease.
Wen H, Deng H, Yang L, Li L, et al · · 2024 · cited 10× · PMID 39412049 · DOI 10.1002/14651858.cd015033.pub2
Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
Gabbia D, De Martin S. · · 2023 · cited 10× · PMID 38132297 · DOI 10.3390/biology12121471
Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease.
Zailaie SA, Khoja BB, Siddiqui JJ, Mawardi MH, et al · · 2024 · cited 5× · PMID 38392965 · DOI 10.3390/ncrna10010010

Verify or expand the search:

Other recruiting trials for NASH - Nonalcoholic Steatohepatitis

Currently open trials in the same condition.

NCT05499949 — The Franciscus Obesity NASH Study · active not recruiting
NCT05023044 — Nonalcoholic Fatty Liver Disease in HIV Database · active not recruiting
NCT04232566 — Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity · recruiting
NCT05165446 — Novel MRE Technique to Assess a Risk Factor for Liver Cancer · active not recruiting
NCT04697810 — Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04781933 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mativa-Tech SA
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04781933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing